LTR Pharma Secures Ethics Committee Approval for Intranasal Spray Study

MT Newswires Live

Dec 03, 2025

LTR Pharma (ASX:LTP) secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.

Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.

The approval allows the company to progress toward patient recruitment in 2026, the filing said.

Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.

Shares rose more than 2% in afternoon trade Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588096146"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588096146\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588096146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 10:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588096146","market":"us","top_or_hot":-1,"title":"LTR Pharma Secures Ethics Committee Approval for Intranasal Spray Study","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.</p><p>Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.</p><p>The approval allows the company to progress toward patient recruitment in 2026, the filing said.</p><p>Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.</p><p>Shares rose more than 2% in afternoon trade Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Secures Ethics Committee Approval for Intranasal Spray Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Secures Ethics Committee Approval for Intranasal Spray Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-03 10:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.</p><p>Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.</p><p>The approval allows the company to progress toward patient recruitment in 2026, the filing said.</p><p>Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.</p><p>Shares rose more than 2% in afternoon trade Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTP.AU","symbol_name":"LTR PHARMA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588096146","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588096146","pubTimestamp":1764730527,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.The approval allows the company to progress toward patient recruitment in 2026, the filing said.Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.Shares rose more than 2% in afternoon trade Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTP.AU":"LTR PHARMA LTD","BK7096":"制药"},"translate_title":"LTR Pharma鼻内喷雾剂研究获得伦理委员会批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":1},"content_text":"LTR Pharma (ASX:LTP) secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.The approval allows the company to progress toward patient recruitment in 2026, the filing said.Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.Shares rose more than 2% in afternoon trade Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}